RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Tonyvanw, Since Neurology originally put the clinical hold in place, and then partially removed it last Fall with the dosing restrictions, shouldn't it first be Neurology to officially remove/reduce the overall dosing restrictions, not just for the AD PET trial as they have done, but generally? Then, based on that decision by Neurology, Psychiatric has to decide on the specifics of the proposed ADHD trial IND protocol.

What I'm trying to figure out is if once Neurology completes their review, Cortex will get an additional confirmation from them that removes/reduces the dosing restrictions generally (beyond the AD PET liberalization) - a development that would be material and require a new press release. Or will we just get a single press release when the IND is filed with Psychiatric, with a blurb included saying that everything is cool with Neurology (though perhaps without specifics)?

The timing of one's reentry into the stock will depend on the above. The scenario I'd rather not see would be if Cortex says nothing further about Neurology's final decision, and then just puts out a press release announcing the filing of the IND with Psychiatric. In that case we're left in the dark as to what Neurology's final ruling was, and we have to presume that the dose was sufficiently liberalized but we won't know that for sure. We'll only know it was likely favorable enough to justify Cortex's filing of the IND, but we won't know if the dosing limits were removed entirely, partially, modestly, etc.